Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7380
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,071.73
    -567.41 (-0.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6838
    -0.0005 (-0.07%)
     

Is It Time to Buy the Dow Jones' 3 Worst-Performing January Stocks?

Is It Time to Buy the Dow Jones' 3 Worst-Performing January Stocks?

Taking a cue from the Dogs of the Dow strategy, let's see if any of the Dow's weakest performers in January are worth buying today. Johnson & Johnson (NYSE: JNJ) is as stable of a blue chip stock as they come, but the healthcare giant faced several negative headlines in January that pushed its shares lower, and its earnings report failed to impress the market. Along with partners, it also canceled its phase 3 Mosaico clinical HIV vaccine trial, because the drug was not effective in preventing HIV infection.